These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. Marseille E; Mitchell JM; Kahn JG PLoS One; 2022; 17(2):e0263252. PubMed ID: 35213554 [TBL] [Abstract][Full Text] [Related]
24. Psychedelic Therapy: A Primer for Primary Care Clinicians-3,4-Methylenedioxy-methamphetamine (MDMA). Shinozuka K; Tabaac BJ; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS Am J Ther; 2024 Mar-Apr 01; 31(2):e141-e154. PubMed ID: 38518271 [TBL] [Abstract][Full Text] [Related]
25. MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. Smith KW; Sicignano DJ; Hernandez AV; White CM J Clin Pharmacol; 2022 Apr; 62(4):463-471. PubMed ID: 34708874 [TBL] [Abstract][Full Text] [Related]
27. Acute subjective effects in LSD- and MDMA-assisted psychotherapy. Schmid Y; Gasser P; Oehen P; Liechti ME J Psychopharmacol; 2021 Apr; 35(4):362-374. PubMed ID: 33853422 [TBL] [Abstract][Full Text] [Related]
28. MDMA-assisted psychotherapy for posttraumatic stress disorder: A promising novel approach to treatment. Vermetten E; Yehuda R Neuropsychopharmacology; 2020 Jan; 45(1):231-232. PubMed ID: 31455855 [No Abstract] [Full Text] [Related]
29. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Feduccia AA; Mithoefer MC Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):221-228. PubMed ID: 29524515 [TBL] [Abstract][Full Text] [Related]
30. The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD. Brewerton TD; Lafrance A; Mithoefer MC Med Hypotheses; 2021 Jan; 146():110367. PubMed ID: 33203569 [TBL] [Abstract][Full Text] [Related]
31. Progress and promise for the MDMA drug development program. Feduccia AA; Holland J; Mithoefer MC Psychopharmacology (Berl); 2018 Feb; 235(2):561-571. PubMed ID: 29152674 [TBL] [Abstract][Full Text] [Related]
32. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Bouso JC; Doblin R; Farré M; Alcázar MA; Gómez-Jarabo G J Psychoactive Drugs; 2008 Sep; 40(3):225-36. PubMed ID: 19004414 [TBL] [Abstract][Full Text] [Related]
33. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. Amoroso T; Workman M J Psychopharmacol; 2016 Jul; 30(7):595-600. PubMed ID: 27118529 [TBL] [Abstract][Full Text] [Related]
34. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil. Jardim AV; Jardim DV; Chaves BR; Steglich M; Ot'alora G M; Mithoefer MC; da Silveira DX; Tófoli LF; Ribeiro S; Matthews R; Doblin R; Schenberg EE Braz J Psychiatry; 2021; 43(2):181-185. PubMed ID: 32638920 [TBL] [Abstract][Full Text] [Related]
35. Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review. Szafoni S; Więckiewicz G; Pudlo R; Gorczyca P; Piegza M Psychiatr Pol; 2022 Aug; 56(4):823-836. PubMed ID: 37074831 [TBL] [Abstract][Full Text] [Related]
36. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
37. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Mitchell JM; Ot'alora G M; van der Kolk B; Shannon S; Bogenschutz M; Gelfand Y; Paleos C; Nicholas CR; Quevedo S; Balliett B; Hamilton S; Mithoefer M; Kleiman S; Parker-Guilbert K; Tzarfaty K; Harrison C; de Boer A; Doblin R; Yazar-Klosinski B; Nat Med; 2023 Oct; 29(10):2473-2480. PubMed ID: 37709999 [TBL] [Abstract][Full Text] [Related]
38. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. Mithoefer MC; Wagner MT; Mithoefer AT; Jerome L; Martin SF; Yazar-Klosinski B; Michel Y; Brewerton TD; Doblin R J Psychopharmacol; 2013 Jan; 27(1):28-39. PubMed ID: 23172889 [TBL] [Abstract][Full Text] [Related]
39. Review of potential psychedelic treatments for PTSD. Henner RL; Keshavan MS; Hill KP J Neurol Sci; 2022 Aug; 439():120302. PubMed ID: 35700643 [TBL] [Abstract][Full Text] [Related]
40. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Nicholas CR; Wang JB; Coker A; Mitchell JM; Klaire SS; Yazar-Klosinski B; Emerson A; Brown RT; Doblin R Drug Alcohol Depend; 2022 Apr; 233():109356. PubMed ID: 35286849 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]